Turning novel biology into first-in-class cancer therapeutics.
Vivace Therapeutics is an oncology-focused small molecule drug discovery and development company based in San Mateo, California. Founded in 2016, the company focuses exclusively on the Hippo-YAP signaling pathway — a key regulator of cell proliferation, programmed cell death, and organ size — which is dysregulated across a wide range of cancers including mesothelioma, meningioma, schwannoma, lung, breast, and hepatocellular carcinoma. Vivace's lead program, VT3989, is a first-in-class YAP/TEAD palmitoylation inhibitor that has demonstrated clinical proof-of-concept in Phase I/II trials for refractory mesothelioma, receiving FDA Fast Track and Orphan Drug designations. The company has raised over $105 million across Series A through D financings and operates with a capital-efficient model leveraging scientific talent across the US and China.
Create a free account to see funding visualizations and detailed round data.
Create Free AccountCreate a free account to see full funding history, valuations, and investor participation.
Create Free AccountCreate a free account to see which investors have funded this company.
Create Free Account